Neomatrix Therapeutics Inc.
Stony Brook, NY
- UEI
- Z9ZTKJPE92R4
- CAGE
- 4KNH8
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 25 Health Sciences Drive, Stony Brook, NY 11790, USA
- Website
- neomatrixtx.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| FY20 new start-JW200170: CNP8 delivered topically in a tyrosine- derived fiber mat to reduce burn injury progression… | Defense Health Agency | $2,923,902 |
Grant awards
Similar vendors
About the company
Neomatrix Therapeutics Inc. is a self-certified small disadvantaged business registered to receive federal contract and grant awards from agencies like the Defense Health Agency. Neomatrix Therapeutics Inc. provides products and services related to biomedical research and the development of advanced wound treatment modalities.
Through prime federal contract awards, Neomatrix Therapeutics Inc. has worked on projects like developing CNP8 delivered topically in a tyrosine-derived fiber mat to reduce burn injury progression, speed wound closure, and mitigate scarring. This $2.9 million fixed price level of effort contract was awarded by the Defense Health Agency with no set-aside designation used. The work is being performed in Stony Brook, New York through September 2025 to support defense health programs and investigate medical solutions for the battlefield.
Through prime federal grant awards, Neomatrix Therapeutics Inc. has conducted research like a Phase 1 randomized, placebo-controlled, single ascending dose study to examine the safety, tolerability, and pharmacokinetics of the compound CNP8 in healthy adults. This $2.2 million project grant is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) and will be completed in Stony Brook, NY by September 2026. Another $1.9 million project grant from the same agency supported IND-enabling studies for a scalable peptide therapy to limit burn conversion and speed wound closure through September 2024.
Quick answers
Is Neomatrix Therapeutics Inc. registered in SAM.gov?
Yes. Neomatrix Therapeutics Inc.'s SAM.gov registration is active through February 11, 2027.
What is Neomatrix Therapeutics Inc.'s CAGE code?
Neomatrix Therapeutics Inc.'s CAGE code is 4KNH8, and its Unique Entity ID (UEI) is Z9ZTKJPE92R4.
What is Neomatrix Therapeutics Inc.'s most recent federal award?
Neomatrix Therapeutics Inc.'s most recent federal grant award is A phase 1 randomized, placebo-controlled, single ascending dose study to examine the safety, tolerability, and… (HT94252311064), from Defense Health Agency, on September 30, 2023.
On GovTribe
See Neomatrix Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors